



RECEIVED

JUN 21 2001

TECH CENTER 1600/2900 PATENT Docket No. 220002059711

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on June 12, 2001.

Patricia Ellison

Patricia Ellison

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Thomas INNERARITY and Jan BOREN

Serial No.: 09/823,418

Filing Date: March 29, 2001

For: METHODS AND TOOLS FOR
IDENTIFYING COMPOUNDS WHICH
MODULATE ATHEROSCLEROSIS BY
IMPACTING LDL-PROTEOGLYCAN
BINDING

Examiner: To Be Assigned

Group Art Unit: 1641

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Number 09/265,222, filed March 5, 1999, and, accordingly, copies are not included herewith. This protocol conforms with 37 C.F.R. § 1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

Documents 21, 28, 33, 44, 70, and 79, listed on the attached Form PTO-1449 were cited in a Search Report (copy attached) directed to a counterpart international or foreign application.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee. Accordingly, a Petition requesting consideration of the Information Disclosure Statement, an authorization to charge our deposit account, and a Certification under 37 C.F.R. § 1.97(e) are provided herein.


Applicants would appreciate the Examiner's initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is to the best of my knowledge and is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 220002059711. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: June 12, 2001

Respectfully submitted,

By: 
Paul S. Naik
Limited Recognition Under 37 CFR
§10.9(b)
(copy of certificate attached)

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5704
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 220002059711

Application Number 09/823,418


Applicant

Thomas INNERARITY and Jan BOREN

Filing Date March 29, 2001

Group Art Unit 1641

Mailing Date June 12, 2001



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	07/28/1987	4,683,195	Mullis et al.			
	2.	07/28/1987	4,683,202	Mullis			
	3.	08/18/1992	5,139,941	Muzyczka et al.			
	4.	09/27/1994	5,350,671	Houghton et al.			
	5.	03/21/1995	5,399,346	Anderson et al.			
	6.	12/03/1996	5,580,859	Felgner et al.			
	7.	08/12/1997	5,656,465	Panicali et al.			
	8.	09/30/1997	5,672,344	Kelley et al.			
	9.	12/22/1998	5,851,529	Guber et al.			

RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	NO
	10.	09/13/1984	WO 84/03506	PCT				
	11.	09/13/1984	WO 84/03564	PCT				
	12.	02/09/1995	WO 95/04064	PCT				
	13.	12/10/1986	0 200 362 B1	Europe				
	14.	12/17/1986	0 201 184 B1	Europe				
	15.	07/22/1987	0 229 701 B1	Europe				

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	16.	<u>Antibodies: A Laboratory Manual.</u> (1988) Harlow, E. and D. Lane, Eds. (Table of Contents).
	17.	Arnold, K. et al., (1992). "Lipoprotein-Receptor Interactions" in <u>Lipoprotein Analysis. A Practical Approach.</u> Converse, C. A. and E. R. Skinner, Eds. Oxford University Press: Oxford. pp. 145-168.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 220002059711	Application Number 09/823,418
	Applicant Thomas INNERARITY and Jan BOREN	
	Filing Date March 29, 2001	Group Art Unit 1641
	Mailing Date June 12, 2001	

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

18.	Basu, S. et al. (1976). "Degradation of Cationized Low Density Lipoprotein and Regulation of Cholesterol Metabolism in Homozygous Familial Hypercholesterolemia Fibroblasts" <i>Proc. Natl. Acad. Sci. USA</i> 73:3178-3182.
19.	Borén, J. et al. (1996). "A Simple and Efficient Method for Making Site-Directed Mutants, Deletions, and Fusions of Large DNA Such as P1 and BAC Clones," <i>Genome Res.</i> 6:1123-1130.
20.	Borén, J. et al. (1998). "Identification of the Low Density Lipoprotein Receptor-Binding Site in Apolipoprotein B100 and the Modulation of its Binding Activity by the Carboxyl Terminus in Familial Defective apo-B100," <i>J. Clin. Invest.</i> 101:1084-1093.
21.	Camejo, G. et al. (1980). "Factors Modulating the Interaction of LDL with an Arterial Lipoprotein Complexing Proteoglycan: The Effect of HDL," <i>Acta. Med. Scand. Suppl.</i> 642:159-164.
22.	Camejo, G. et al. (1988). "Identification of Apo B-100 Segments Mediating the Interaction of Low Density Lipoproteins with Arterial Proteoglycans," <i>Arteriosclerosis</i> 8:368-377.
23.	Camejo, G. et al. (1993). "Binding of Low Density Lipoproteins by Proteoglycans Synthesized by Proliferating and Quiescent Human Arterial Smooth Muscle Cells," <i>J. Biol. Chem.</i> 268:14131-14137.
24.	Capecchi, M. (1989). "Altering the Genome by Homologous Recombination," <i>Science</i> 244:1288-1292.
25.	Cardin, A. et al. (1987). "Physical-Chemical Interaction of Heparin and Human Plasma Low-Density Lipoproteins," <i>Biochemistry</i> 26:5513-5518.
26.	Cardoso, L.E. et al. (1994). "Glycosaminoglycan Fractions from Human Arteries Presenting Diverse Susceptibilities to Atherosclerosis Have Different Binding Affinities to Plasma LDL," <i>Arterioscler. Thromb.</i> 14:115-124.
27.	Chang, Y. et al. (1983). "Proteoglycans Synthesized by Smooth Muscle Cells Derived from Monkey (<i>Macaca nemestrina</i>) Aorta," <i>J. Biol. Chem.</i> 258:5679-5688.
28.	Christner, J.E. et al. (1990). "A Competitive Assay of Lipoprotein:Proteoglycan Interaction Using a 96-Well Microtitration Plate," <i>Analytical Biochem.</i> 184:388-394.
29.	Corsini, A. et al. (1987). "Receptor Binding Activity of Lipid Recombinants of Apolipoprotein B-100 Thrombolytic Fragments" <i>J. Lipid Res.</i> 28:1410-1423.
30.	Costa, G. et al. (1994). "Polishing with T4 or <i>Pfu</i> Polymerase Increases the Efficiency of Cloning of PCR Fragments," <i>Nucleic Acids Res.</i> 22:2423
31.	Deng, W. et al. (1992). "Site-Directed Mutagenesis of Virtually Any Plasmid by Eliminating a Unique Site," <i>Anal. Biochem.</i> 200:81-88.
32.	Edwards, I. et al. (1993). "Lipoprotein Lipase Enhances the Interaction of Low Density Lipoproteins with Artery-Derived Extracellular Matrix Proteoglycans," <i>J. Lipid Res.</i> 34:1155-1163.
33.	Eisenberg, S. et al. (1992). "Lipoprotein Lipase Enhances Binding of Lipoproteins to Heparan Sulfate on Cell Surfaces and Extracellular Matrix," <i>J. Clin. Invest.</i> 90:2013-2021.

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.	



Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Docket Number 220002059711	Application Number 09/823,418
	Applicant Thomas INNERARITY and Jan BOREN	
	Filing Date March 29, 2001	Group Art Unit 1641
	Mailing Date June 12, 2001	

34.	Gaffney, D. et al. (1995). "Independent Mutations at Codon 3500 of the Apolipoprotein B Gene Are Associated with Hyperlipidemia," <i>Arterioscler. Thromb. Vasc. Biol.</i> 15:1025-1029.
35.	Galis, Z. et al. (1993). "Co-Localization of Aortic Apolipoprotein B and Chondroitin Sulfate in an Injury Model of Atherosclerosis," <i>Am J. Pathol.</i> 142:1432-1438.
36.	Geysen, H.M. et al. (1984). "Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid," <i>Proc. Natl. Acad. Sci. USA</i> 81:3998-4002.
37.	Goldstein, J. et al. (1985). "Receptor-Mediated Endocytosis: Concepts Emerging from the LDL Receptor System," <i>Annu. Rev. Cell Biol.</i> 1:1-39.
38.	Hirose, N. et al. (1987). "Isolation and Characterization of Four Heparin-Binding Cyanogen Bromide Peptides of Human Plasma Apolipoprotein B," <i>Biochemistry</i> 26:5505-5512.
39.	Hobbs, H. et al. (1992). "Molecular Genetics of the LDL Receptor Gene in Familial Hypercholesterolemia," <i>Hum. Mutat.</i> 1:445-466.
40.	Hoff, H et al. (1986). "Plasma Low Density Lipoprotein Accumulation in Aortas of Hypercholesterolemic Swine Correlates with Modifications in Aortic Glycosaminoglycan Composition," <i>Atherosclerosis.</i> 61:231-236.
41.	Hoff, H. et al. (1983). "Apolipoprotein B Localization in Coronary Atherosclerotic Plaques from Cynomolgus Monkeys," <i>Artery</i> 12:104-116.
42.	Hu, G. (1993). "DNA Polymerase-Catalyzed Addition of Nontemplated Extra Nucleotides to the 3' End of a DNA Fragment," <i>DNA and Cell Biology</i> 12:763-770.
43.	Hurt, E. et al. (1987). "Effect of Arterial Proteoglycans on the Interaction of LDL with Human Monocyte-Derived Macrophages," <i>Atherosclerosis</i> 67:115-126.
44.	Hurt, E. et al. (1990). "Interaction of LDL with Human Arterial Proteoglycans Stimulates its Uptake by Human Monocyte-Derived Macrophages," <i>J. Lipid Res.</i> 31:443-454.
45.	Hurt-Camejo, E. et al. (1997). "Cellular Consequences of the Association of apoB Lipoproteins with Proteoglycans," <i>Arterioscler Thromb Vasc Biol.</i> 17:1011-1017.
46.	Innerarity, T. et al. (1987). "Familial Defective Apolipoprotein B-100: Low Density Lipoproteins with Abnormal Receptor Binding," <i>Proc. Natl. Acad. Sci. USA</i> 84:6919-6923.
47.	Innerarity, T. et al. (1990). "Familial Defective Apolipoprotein B-100: A Mutation of Apolipoprotein B that Causes Hypercholesterolemia," <i>J. Lipid Res.</i> 31:1337-1349.
48.	Ismail, N. et al. (1994). "Lipoprotein-Proteoglycan Complexes from Injured Rabbit Aortas Accelerate Lipoprotein Uptake by Arterial Smooth Muscle Cells," <i>Atherosclerosis</i> 105:79-87.
49.	Johnstone, A. et al. (1996). "Purification of Immunoglobulins," <i>Immunochemistry in Practice.</i> Blackwell Scientific Publications; Oxford. p. 69.
50.	Knott, T. et al (1985). "Human Apolipoprotein B: Structure of Carboxyl-Terminal Domains, Sites of Gene Expression, and Chromosomal Localization," <i>Science.</i> 230:37-43.
51.	Knott, T. et al. (1986). "Complete Protein Sequence and Identification of Structural Domains of Human Apolipoprotein B," <i>Nature</i> 323:734-738.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 220002059711

Application Number 09/821,418

Applicant

Thomas INNERARITY and Jan BOREN

Filing Date March 29, 2001

Group Art Unit 1641

Mailing Date June 12, 2001


RECEIVED
JUN 24 2002
TECH CENTER 1600/2900

52.	Kunkel, Thomas A. (1985). "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 82:488-492.
53.	Lindén, T. et al. (1989). "Affinity of LDL to a Human Arterial Proteoglycan Among Male Survivors of Myocardial Infarction," <i>Eur. J. Clin. Invest.</i> 19:38-44.
54.	Linton, M. et al. (1993). "Transgenic Mice Expressing High Plasma Concentrations of Human Apolipoprotein B100 and Lipoprotein (a)" <i>J. Clin. Invest.</i> 92:3029-3037.
55.	Mahley, R. et al. (1977). "Inhibition of Lipoprotein Binding to Cell Surface Receptors of Fibroblasts Following Selective Modification of Arginyl Residues in Arginine-Rich and B Apoproteins," <i>J. Biol. Chem.</i> 252:7279-7287.
56.	Mahley, R. et al. (1979). "Interaction of Plasma Lipoproteins Containing Apolipoproteins B and E with Heparin and Cell Surface Receptors," <i>Biochem. Biophys. Acta.</i> 575:81-91.
57.	McCormick, S. et al. (1994). "Expression of P1 DNA in Mammalian Cells and Transgenic Mice," <i>Genet. Anal. Tech. Appl.</i> 11:158-164.
58.	Merrilees, M.J. et al. (1990). "Glycosaminoglycan Synthesis by Smooth Muscle Cells of Differing Phenotype and their Response to Endothelial Cell Conditioned Medium," <i>Atherosclerosis</i> 81:245-254.
59.	<u>Methods in Enzymology</u> (1979). Colowick, S. and N. Kaplan, Eds. Academic Press. (Table of Contents).
60.	Milne, R. et al. (1983). "Characterization of Monoclonal Antibodies Against Human Low Density Lipoprotein," <i>Arteriosclerosis</i> 3:23-30.
61.	<u>Molecular Cloning: A Laboratory Manual</u> . (1989). Second Edition. J. Sambrook et al., Eds. Cold Spring Harbor Laboratory Press: Cold Spring Harbor. (Table of Contents).
62.	Mullis, K.B. et al. (1987). "Specific Synthesis of DNA <i>In Vitro</i> Via a Polymerase-Catalyzed Chain Reaction" <i>Methods in Enzymology</i> 155:335-350.
63.	Nelson, M. et al. (1992). "Use of DNA Methyltransferase/Endonuclease Enzyme Combinations for Megabase Mapping of Chromosomes" <i>Methods Enzymol.</i> 216:279-303.
64.	Nivelstein-Post, P. et al. (1994). "An Ultrastructural Study of Lipoprotein Accumulation in Cardiac Valves of the Rabbit" <i>Arterioscler. Thromb.</i> 14:1151-1161.
65.	<u>Nucleic Acid Hybridisation. A Practical Approach</u> . (1985). Hames, B.D. & S. J. Higgins, Eds. IRL Press. (Table of Contents).
66.	<u>Oligonucleotide Synthesis. A Practical Approach</u> . (1984). Gait, M.J. Ed., IRL Press. (Table of Contents).
67.	Olsson, U. et al. (1994). "Possible Functional Interactions of Apolipoprotein B-100 Segments that Associate with Cell Proteoglycans and the ApoB/E Receptor," (1997) <i>Arterioscler. Throm. Vasc. Biol.</i> 17:149-155.
68.	Paananen, K. et al. (1994). "Proteolysis and Fusion of Low Density Lipoprotein Particles Independently Strengthen their Binding to Exocytosed Mast Cell Granules," <i>J. Biol. Chem.</i> 269:2023-2031.
69.	<u>PCR Technology</u> . (1989). Erlich, H.A. Ed. Stockton Press. (Table of Contents).
70.	Pentikäinen, M.O. et al. (1997). "The Proteoglycan Decorin Links Low Density Lipoproteins with Collagen Type I," <i>J. Biol. Chem.</i> 272:7633-7638.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



Form PTO-1449

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 220002059711

Application Number 09/823,418

Applicant

Thomas INNERARITY and Jan BOREN

Filing Date March 29, 2001

Group Art Unit 1641

Mailing Date June 12, 2001

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

71.	Protein Purification: Principles and Practice. 2nd Edition. Scopes, R.K., Ed. (1987) Springer-Verlag. (Table of Contents).
72.	Pullinger, C. et al. (1995). "Familial Ligand-Defective Apolipoprotein B" <i>J. Clin. Invest.</i> 95:1225-1234.
73.	Radhakrishnamurthy, B. et al. (1990). "Arterial Wall Proteoglycans - Biological Properties Related to Pathogenesis of Atherosclerosis," <i>Eur. Heart J.</i> 11(Suppl E):148-157.
74.	Ross, R. (1995). "Cell Biology of Atherosclerosis," <i>Annu. Rev. Physiol.</i> 57:791-804.
75.	Saiki, R. et al. (1988). "Primer-Directed Enzymatic Amplification of DNA with a Thermostable DNA Polymerase," <i>Science</i> 239:487-491.
76.	Schönherr, E. et al. (1993). "Platelet-Derived Growth Factor and Transforming Growth Factor- β 1 Differentially Affect the Synthesis of Biglycan and Decorin by Monkey Arterial Smooth Muscle Cells," <i>Arterioscler. Thromb.</i> 13:1026-1036.
77.	Schönherr, E. et al., (1991). "Effects of Platelet-Derived Growth Factor and Transforming Growth Factor- β 1 on the Synthesis of a Large Versican-Like Chondroitin Sulfate Proteoglycan by Arterial Smooth Muscle Cells," <i>J. Biol. Chem.</i> 266:17640-17647.
78.	Steele, R. et al. (1987). "Artery Wall Derived Proteoglycan-Plasma Lipoprotein Interaction: Lipoprotein Binding Properties of Extracted Proteoglycans," <i>Atherosclerosis</i> 65:51-62.
79.	van Barlingen, H.H. et al. (1996). "Lipoprotein Lipase-Enhanced Binding of Human Triglyceride-Rich Lipoproteins to Heparan Sulfate: Modulation by Apolipoprotein E and Apolipoprotein C," <i>Journal of Lipid Res.</i> 37:754-763.
80.	Vandeyar, M.A. et al., (1988). "A Simple and Rapid Method for the Selection of Oligodeoxynucleotide-Directed Mutants," <i>Gene</i> 65:129-133.
81.	Walton, K. et al. (1968). "Histological and Immunofluorescent Studies on the Evolution of the Human Atheromatous Plaque," <i>J. Atheroscler. Res.</i> 8:599-624.
82.	Weiner, M. et al. (1994). "Site-Directed Mutagenesis of Double-Stranded DNA by the Polymerase Chain Reaction," <i>Gene</i> 151:119-123.
83.	Weisgraber, K. et al. (1978). "Role of the Lysine Residues of Plasma Lipoproteins in High Affinity Binding to Cell Surface Receptors on Human Fibroblasts," <i>J. Biol. Chem.</i> 253:9053-9062.
84.	Weisgraber, K. et al. (1986). "Human Apolipoprotein E: Determination of the Heparin Binding Sites of Apolipoprotein E3," <i>J. Biol. Chem.</i> 261:2068-2076.
85.	Weisgraber, K. et al. (1987). "Human Apolipoprotein B-100 Heparin-Binding Sites," <i>J. Biol. Chem.</i> 262:11097-11103.
86.	Williams, K.J. et al. (1995). "The Response-to-Retention Hypothesis of Early Atherogenesis," <i>Arterioscler. Thromb. Vasc Biol.</i> 15:551-561.
87.	Yao, Z. et al. (1992). "Elimination of Apolipoprotein B48 Formation in Rat Hepatoma Cell Lines Transfected with Mutant Human Apolipoprotein B cDNA Constructs," <i>J. Biol. Chem.</i> 267:1175-1182.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.



RECEIVED

JUN 21 2001

TECH CENTER 1600/2900

PTO/SB/21 (08-00)

Approved for use through 10/31/02. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/823,418	
	Filing Date	March 29, 2001	
	First Named Inventor	Thomas INNERARITY	
	Group Art Unit	1641	
	Examiner Name	To Be Assigned	
Total Number Of Pages In This Submission	12	Attorney Docket No.	220002059711

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	1. Form PTO-1449 - 5 pages
<input checked="" type="checkbox"/> Information Disclosure Statement - 3 pages	<input type="checkbox"/> Request for Refund	2. Copy of International Search Report - 2 pages
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	3. Copy of Limited Recognition Under 37 CFR §10.9(b) - 1 page
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		4. Return postcard
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

RECEIVED

JUN 24 2002

TECH CENTER 1600/2900

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
Signature	Paul S. Naik (Limited Recognition Under 37 CFR §10.9(b), copy of certificate attached)
Date	June 12, 2001

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on June 12, 2001.

Patricia Ellison

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.